Abstract:Background: The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) predicts the risk of malignancy for the different categories of the ultrasound-guided fine-needle aspiration biopsy (FNAB). The objective of this study is to investigate the efficiencies of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E mutation test and the TBSRTC categories in distinguishing between benign and malignant thyroid nodules. Methods: In this study, 362 ultrasound-guided fine-needle aspiration (FNA) samples from 344 patients aged from 17 to 76 years old were retrospectively reviewed. The patients were classified into six groups (I-VI) according to the TBSRTC system. The amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) was used to evaluate the BRAF V600E mutation level in total 362 samples. Among of the 344 patients, 128 patients (131 thyroid nodules) who underwent surgeries were followed by histopathological examination. The predictive values of the BRAF V600E mutation test and TBSRTC categories were evaluated in these 131 thyroid nodules. Results: The median ages of the patients in the TBSRTC IV-VI group were smaller than those in the TBSRTC I-III groups. The proportion of nodules over 1 cm was larger than it in the TBSRTC IV group compared to the other groups. Significant differences in BRAF V600E mutation were observed (P < .001) among these six groups. The sensitivity (89.57%) for the detection of malignant thyroid nodules, negative predictive value (NPV; 45.45%) for the detection of benign nodules, and accuracy (86.26%) for distinguishing between benign and malignant thyroid nodules increased by combining the BRAF V600E mutation test and TBSRTC system when compared with the BRAF V600E mutation test and TBSRTC system respectively. The BRAF V600E mutation test alone demonstrated the increased positive predictive value (PPV; 98.91%) and specificity (93.75%) for the detection of malignant thyroid nodules compared to the TBSRTC method (alone or in combination with the BRAF V600E method). Conclusion: In summary, significant differences in age, nodule diameter, and BRAF V600E mutation were noted among the six categories of the TBSRTC system. The combination of the BRAF V600E mutation test and TBSRTC system demonstrated increases in the NPV, sensitivity, and accuracy, while the BRAF V600E method proved superiority to the TBSRTC system with regard to the PPV and specificity.

Comparative efficiency of differential diagnostic methods for the identification of BRAF V600E gene mutation in papillary thyroid cancer (Review)

[Diagnostic Values of BRAF(V600E) Mutation Analysis and Bethesda System for Reporting Thyroid Cytopathology in Thyroid Nodules with TIRADS 4 and 5].

BRAF V600E Mutation and the Bethesda System for Reporting Thyroid Cytopathology of Fine-Needle Aspiration Biopsy for Distinguishing Benign from Malignant Thyroid Nodules

Use of the BRAF V600E Mutation in Fine-Needle Aspirations of Thyroid Nodules

The Features of Contrast Enhanced Ultrasound and BRAF V600E in Papillary Thyroid Carcinoma.

Diagnostic value of contrast‐enhanced ultrasound combined with BRAF V600E mutation for cytologically indeterminate thyroid nodules

Comparison of Diagnostic Methods for the Detection of a BRAF Mutation in Papillary Thyroid Cancer

Diagnostic Value of BRAF (V600e)-Mutation Analysis in Fine-Needle Aspiration of Thyroid Nodules: a Meta-Analysis.

Efficient Detection of the V600E Mutation of the BRAF Gene in Papillary Thyroid Carcinoma Using Multiplex Allele-Specific Polymerase Chain Reaction Combined with Denaturing High-Performance Liquid Chromatography

The Role of BRAF in the Pathogenesis of Thyroid Carcinoma.

BRAF V600E mutation and expression of its protein in papillary thyroid carcinoma

Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis

A More Sensitive Platform for the Detection of Low-Abundance Braf(V600e) Mutations

Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAFV600E Mutation in Papillary Thyroid Carcinoma

Brafv600e Mutation in Papillary Thyroid Microcarcinoma: A Meta-Analysis

Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAF V600E mutation in papillary thyroid carcinoma

Effect of BRAF V600E Mutation Detection of Fine-Needle Aspiration Biopsy on Diagnosis and Treatment Guidance of Papillary Thyroid Carcinoma.

The clinical progress on association between BRAF V600E mutation and thyroid papillary carcinoma

Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma

Detection of BRAF V600E Mutation in Fine-Needle Aspiration Fluid of Papillary Thyroid Carcinoma by Droplet Digital PCR.

Targeting of the BRAF gene in papillary thyroid carcinoma (Review)